Worth reading
88Important
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
26
営業利益前期比増加率（％）Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFiscal year ending December 202515 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥20,947 million+14.9%
Operating profit¥5,748 million+26.0%
Ordinary income¥6,051 million+29.2%
Net income¥5,028 million+119.4%
Selling, general and administrative expenses¥7,229 million
Gross Profit Margin
Rate62.0%
Year on year against the same period last yearUp 1.1 percentage points
Operating profit margin
Rate27.4%
Year on year against the same period last year2.4ポイント増
Results for the three months of the current quarter
Net Sales
¥5,959 million
Operating profit
¥1,500 million
Operating profit margin25.2%
Full-year earnings forecast
Fiscal year ending December 2026
Net Sales
¥22,500 million
Operating profit
¥6,500 million
Ordinary income
¥6,550 million
Net income
¥4,600 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Above planBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales密着向上剤、エッチング剤、その他薬品、機械売上、資材売上、その他売上、為替の影響を要因とする増減分析を掲載。要因別金額は判読可能な形で明示されていない。
Operating profit薬品売上・数量、薬品粗利益率、機械売上、機械粗利益率、資材およびその他売上、資材およびその他粗利益率、販管費、為替の影響（粗利・販管費）を要因とする分析を掲載。要因別金額は判読可能な形で明示されていない。
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate
NTD4.95
RMB21.24
HKD19.36
THB4.67
EUR175.76
USD151.02
Number of versions半導体PKG基板、CZシリーズ、化学密着向上剤の需要拡大を見込む
New initiatives
- The Kitakyushu Plant is scheduled to begin operations in December 2026, with maximum production capacity of 2,500 tons per month.
- 半導体パッケージ基板向け技術をインターポーザー・高周波基板へ展開
- 2027年12月期の中期経営計画目標を修正
- Phase2の配当方針を連結配当性向35%以上かつDOE4.0%以上に変更
Key KPIsA metric the company considers important as a management benchmark.
- 薬品売上高¥20,211 millionYear on year against the same period last year+15.6%
- 薬品出荷量47,717 tonYear on year against the same period last year+13.4%
- Overseas revenue ratio65.3 %Year on year against the same period last year前年同一期間63.4%
- ROE17.5 %Year on year against the same period last year8.6ポイント増
- EBITDA¥7,302 millionYear on year against the same period last year+36.1%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Shipment volume
47,717 ton+13.4%
Segment results
By product type
ChemicalsFY2025四半期売上：4,237、4,787、5,534、5,652百万円
MachineryFY2025四半期売上：49、7、30、225百万円
MaterialsFY2025四半期売上：128、160、33、80百万円
OtherFY2025四半期売上：8、7、2、1百万円
Regional breakdown
JapanFY2025四半期売上：1,594、1,756、2,191、2,284百万円
Taiwan860、954、1,006、1,065百万円
China1,370、1,607、1,835、1,919百万円
Europe400、382、269、340百万円
Thailand197、262、297、349百万円
Medium-term management plan targets
2027年12月期修正目標
Net Sales250億円（コア事業245億円、応用展開5億円）
Operating profit margin26〜30%
ROE13〜16%
Comparison with actual results2025年12月期実績：売上高209億円、営業利益率27.4%、ROE17.5%
Financial targets
ROE target13〜16%
Actual ROE17.5%
Number of stores and locations
Number of locations at period-end国内3拠点、海外5拠点
Number of employees
Number of Employees508 consolidated, 292 non-consolidated
Capital expenditures
¥2,846 million2025年12月期実績
Annual Dividend
Annual dividend per share¥96
Interim and Year-End Breakdown中間25円、期末71円
Payout ratio
Rate38.1%
DOE4.0% or more
Acquisition of treasury shares
Amount under the acquisition limit2025年取得額1,292百万円。今後は機動的に実施
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ending December 2025 |
| Net Sales | ¥20,947 million (YoY +14.9%) |
| Operating profit | ¥5,748 million (YoY +26.0%) |
| Ordinary income | ¥6,051 million (YoY +29.2%) |
| Net income | ¥5,028 million (YoY +119.4%) |
| Gross Profit Margin | Rate 62.0% / Year on year against the same period last year Up 1.1 percentage points |
| Operating profit margin | Rate 27.4% / Year on year against the same period last year 2.4ポイント増 |
| Selling, general and administrative expenses | ¥7,229 million |
| Results for the three months of the current quarter | Net Sales ¥5,959 million / Operating profit ¥1,500 million / Operating profit margin 25.2% |
| Full-year earnings forecast | Subject Fiscal year ending December 2026 / Net Sales ¥22,500 million / Operating profit ¥6,500 million / Ordinary income ¥6,550 million / Net income ¥4,600 million |
| Self-assessment against the plan | Above plan |
| Segment results | By product type Chemicals FY2025四半期売上：4,237、4,787、5,534、5,652百万円 / Machinery FY2025四半期売上：49、7、30、225百万円 / Materials FY2025四半期売上：128、160、33、80百万円 / Other FY2025四半期売上：8、7、2、1百万円 / Regional breakdown Japan FY2025四半期売上：1,594、1,756、2,191、2,284百万円 / Taiwan 860、954、1,006、1,065百万円 / China 1,370、1,607、1,835、1,919百万円 / Europe 400、382、269、340百万円 / Thailand 197、262、297、349百万円 |
| Breakdown of Factors Affecting the Change | Net Sales 密着向上剤、エッチング剤、その他薬品、機械売上、資材売上、その他売上、為替の影響を要因とする増減分析を掲載。要因別金額は判読可能な形で明示されていない。 / Operating profit 薬品売上・数量、薬品粗利益率、機械売上、機械粗利益率、資材およびその他売上、資材およびその他粗利益率、販管費、為替の影響（粗利・販管費）を要因とする分析を掲載。要因別金額は判読可能な形で明示されていない。 |
| Key KPIs | Indicator name 薬品売上高 / Value ¥20,211 million / Year on year against the same period last year ¥15.6 million, Indicator name 薬品出荷量 / Value 47,717 ton / Year on year against the same period last year 13.4 ton, Indicator name Overseas revenue ratio / Value 65.3 % / Year on year against the same period last year 前年同一期間63.4%, Indicator name ROE / Value 17.5 % / Year on year against the same period last year 8.6ポイント増, Indicator name EBITDA / Value ¥7,302 million / Year on year against the same period last year ¥36.1 million |
| Unit price and quantity metrics | Shipment volume 47,717 ton (YoY +13.4%) / Unit price Not disclosed |
| Number of stores and locations | Number of locations at period-end 国内3拠点、海外5拠点 / Number of store openings and closures during the period Not disclosed |
| Number of employees | Number of Employees 508 consolidated, 292 non-consolidated / Changes during the period and hiring plan Not disclosed |
| Assumptions Underlying the Business Outlook | Exchange rate NTD 4.95 / RMB 21.24 / HKD 19.36 / THB 4.67 / EUR 175.76 / USD 151.02 / Number of versions 半導体PKG基板、CZシリーズ、化学密着向上剤の需要拡大を見込む |
| Medium-term management plan targets | Subject 2027年12月期修正目標 / Net Sales 250億円（コア事業245億円、応用展開5億円） / Operating profit margin 26〜30% / ROE 13〜16% / Comparison with actual results 2025年12月期実績：売上高209億円、営業利益率27.4%、ROE17.5% |
| Financial targets | ROE target 13〜16% / Actual ROE 17.5% / Equity ratio Not disclosed / ROIC Not disclosed / Debt-to-equity ratio Not disclosed |
| Annual Dividend | Annual dividend per share ¥96 / Interim and Year-End Breakdown 中間25円、期末71円 |
| Payout ratio | Rate 38.1% / Total payout ratio Not disclosed / DOE 4.0% or more |
| Acquisition of treasury shares | Amount under the acquisition limit 2025年取得額1,292百万円。今後は機動的に実施 / Number of Shares Not disclosed / Period Not disclosed |
| Capital expenditures | 2,846 百万円（2025年12月期実績） |
| New initiatives | The Kitakyushu Plant is scheduled to begin operations in December 2026, with maximum production capacity of 2,500 tons per month., 半導体パッケージ基板向け技術をインターポーザー・高周波基板へ展開, 2027年12月期の中期経営計画目標を修正, Phase2の配当方針を連結配当性向35%以上かつDOE4.0%以上に変更 |
Items this document does not state (5)
Progress against full-year forecastRisk amount incorporated into the outlookOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.会社は、生成AI関連の需要拡大など好調な市場環境、高付加価値製品の需要拡大、薬品の出荷量増加、為替の影響を挙げている。薬品売上高は前期比15.6％増、出荷量は同13.4％増となった。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.